Swedish Orphan Biovitrum AB (publ) Stock Price, News & Analysis (OTCMKTS:BIOVF) $21.05 0.00 (0.00%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$21.05▼$21.0550-Day Range$18.58▼$21.0552-Week Range$18.25▼$26.48VolumeN/AAverage Volume76 shsMarket Capitalization$6.21 billionP/E Ratio24.20Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest About Swedish Orphan Biovitrum AB (publ) Stock (OTCMKTS:BIOVF)Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to treat paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.Read More BIOVF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOVF Stock News HeadlinesNovember 23, 2023 | morningstar.comSwedish Orphan Biovitrum AB BIOVFNovember 1, 2023 | finance.yahoo.comSobi has completed the issuances of series C sharesNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 30, 2023 | msn.comSwedish Orphan Biovitrum AB Non-GAAP EPS of SEK0.54, revenue of SEK5.17BOctober 30, 2023 | finance.yahoo.comSwedish Orphan Biovitrum (BIOVF) Q3 Earnings Miss EstimatesOctober 30, 2023 | finance.yahoo.comSobi publishes Q3 2023 report: Strong revenue and solid performanceOctober 27, 2023 | finance.yahoo.comReminder: Invitation: Sobi's Q3 2023 reportOctober 18, 2023 | finance.yahoo.comInvitation: Sobi's Q3 2023 reportNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comSeptember 15, 2023 | finance.yahoo.comReminder: Sobi KOL investor event: Advancing the standard of care in haemophiliaSeptember 8, 2023 | finance.yahoo.comSobi KOL investor event: Advancing the standard of care in haemophiliaAugust 29, 2023 | finance.yahoo.comIs Swedish Orphan Biovitrum (BIOVF) Stock Undervalued Right Now?August 22, 2023 | finance.yahoo.comSobi resolves on a rights issue of approximately SEK 6,024 millionAugust 15, 2023 | finance.yahoo.comBulletin from Swedish Orphan Biovitrum (Sobi)'s Extraordinary General Meeting (EGM)July 19, 2023 | tmcnet.comNotice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)July 18, 2023 | finance.yahoo.comSwedish Orphan Biovitrum (BIOVF) Beats Q2 Earnings and Revenue EstimatesJuly 18, 2023 | prnewswire.comSobi publishes Q2 2023 report: Growth and pipeline expansionJuly 17, 2023 | markets.businessinsider.comSwedish Orphan Biovitrum AB earnings: here's what Wall Street expectsJuly 14, 2023 | finance.yahoo.comSobi KOL investor event: the journey for Vonjo®July 11, 2023 | finance.yahoo.comInvitation: Sobi's Q2 2023 reportJune 25, 2023 | finance.yahoo.comSwedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosingJune 24, 2023 | finance.yahoo.comSobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.June 20, 2023 | finance.yahoo.comThe Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive programmeJune 2, 2023 | finance.yahoo.comSobi to present new data at the 2023 EHA congressMay 30, 2023 | finance.yahoo.comCTI BioPharma Announces Cancellation of its 2023 Annual Meeting of StockholdersMay 30, 2023 | finance.yahoo.comIs Alcon (ALC) Stock Outpacing Its Medical Peers This Year?May 19, 2023 | finance.yahoo.comEMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia ASee More Headlines Receive BIOVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/30/2023Today11/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry N/A Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BIOVF CUSIPN/A CIKN/A Webwww.sobi.com Phone(468) 697-2000FaxN/AEmployees1,612Year Founded2001Profitability EPS (Most Recent Fiscal Year)$0.87 Trailing P/E Ratio24.20 Forward P/E Ratio22.88 P/E GrowthN/ANet Income$261.43 million Net Margins13.05% Pretax Margin19.83% Return on Equity10.85% Return on Assets4.94% Debt Debt-to-Equity Ratio0.61 Current Ratio0.59 Quick Ratio0.37 Sales & Book Value Annual Sales$1.86 billion Price / Sales3.33 Cash Flow$1.88 per share Price / Cash Flow11.19 Book Value$8.91 per share Price / Book2.36Miscellaneous Outstanding Shares295,150,000Free FloatN/AMarket Cap$6.21 billion OptionableNot Optionable Beta0.47 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Guido Oelkers (Age 58)CEO & President Comp: $22.78MMr. Henrik Stenqvist (Age 56)Chief Financial Officer Mr. Torbjörn Hallberg (Age 54)General Counsel & Head of Legal Affairs Mr. Daniel Rankin (Age 43)Head of Strategy & Corporate Development Pablo de Mora (Age 55)Head of Global Marketing & Access Ms. Lena Bjurner (Age 55)Head of Human Resources Mr. Armin Reininger M.D. (Age 66)Ph.D., Senior Scientific & Medical Advisor Mr. Norbert Oppitz (Age 56)Head of International Mr. Sofiane Fahmy (Age 51)Head of Europe Mr. Duane H. Barnes (Age 63)Head of North America More ExecutivesKey CompetitorsGlobus MedicalNYSE:GMEDShockwave MedicalNASDAQ:SWAVAmplifonOTCMKTS:AMFPFThe Ensign GroupNASDAQ:ENSGEncompass HealthNYSE:EHCView All Competitors BIOVF Stock Analysis - Frequently Asked Questions Should I buy or sell Swedish Orphan Biovitrum AB (publ) stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOVF shares. View BIOVF analyst ratings or view top-rated stocks. How have BIOVF shares performed in 2023? Swedish Orphan Biovitrum AB (publ)'s stock was trading at $21.15 on January 1st, 2023. Since then, BIOVF stock has decreased by 0.5% and is now trading at $21.05. View the best growth stocks for 2023 here. Are investors shorting Swedish Orphan Biovitrum AB (publ)? Swedish Orphan Biovitrum AB (publ) saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 570,700 shares, an increase of 8.5% from the October 15th total of 526,200 shares. Based on an average daily trading volume, of 400 shares, the days-to-cover ratio is currently 1,426.8 days. View Swedish Orphan Biovitrum AB (publ)'s Short Interest. How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter? Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) posted its earnings results on Monday, October, 30th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by $0.04. The firm had revenue of $478.11 million for the quarter, compared to analyst estimates of $443.96 million. Swedish Orphan Biovitrum AB (publ) had a trailing twelve-month return on equity of 10.85% and a net margin of 13.05%. How do I buy shares of Swedish Orphan Biovitrum AB (publ)? Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:BIOVF) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Swedish Orphan Biovitrum AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.